Lupin Limited has informed the Exchange regarding a press release dated February 23, 2026, titled "Lupin Receives European Commission Approval for Biosimilar Ranibizumab".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.2 pts more than Nifty Midcap 150 and 1.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin has received European Commission (EC) approval for its biosimilar ranibizumab, marketed as Ranluspec, available in both vials and pre-filled syringes. Ranibizumab is used to treat conditions including wet age-related macular degeneration, diabetic macular edema, and other retinal disorders. The product will be commercialized across the European Union (excluding Germany) by Sandoz, and in France jointly by Sandoz and Biogaran. This approval follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP). Lupin management called it a milestone validating the company's scientific standards in biologics.
Positive for shareholders — EC approval opens access to a major regulated market for Lupin's biosimilars portfolio and validates its biotechnology capabilities. The partnership with Sandoz, a leading global generics player, provides strong commercial reach in Europe, which could support future revenue growth in the biosimilars segment.